Stock Ratings / Health Care / IRLA / dividends

XFOR (35) ALEC (32) SCTX (50) KYTX (42) ⌘ Pro Terminal →

IRulya Therapeutics Inc. (IRLA) Dividend Safety Gauge & 10-Year DRIP Compounder

$31.62 -4.05% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

IRulya Therapeutics Inc. (IRLA) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $342.8M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-11.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for IRLA)Realized 20D OHLCV Swing Band: ±12.5%

CASH DIVIDEND + BUYBACK YIELD

0.6% Total Yield

0% Cash ($0.00/yr) + 0.6% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $17,081

Est. Year-10 Shareholder Yield: $102/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.6K

Yr 1

$11.1K

Yr 2

$11.7K

Yr 3

$12.4K

Yr 4

$13.1K

Yr 5

$13.8K

Yr 6

$14.5K

Yr 7

$15.3K

Yr 8

$16.2K

Yr 9

$17.1K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring IRLA)

✓Walkthrough of IRLA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

IRLA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +20.69%▲ ASCENDING CHANNEL

2026-10-30O $30.67H $34.40L $30.00C $31.62VOL 98.0K

RES: $41.99SUP: $26.94SMA50: $31.07SMA200: $54.46

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

IRLA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 IRLA Butterfly Map → + Track IRLA →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on IRLA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for IRLA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for IRLA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IRLA)

Health Care Rank #889 of 1016 ⚔️ XFOR vs IRLA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (IRLA vs. XFOR, ALEC, SCTX, KYTX)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, IRulya Therapeutics Inc. (IRLA) ranks #889 by composite RQD confidence (32/100, grade E) and #504 by equity capitalization ($342.8M). Within this direct 5-issuer industry benchmark cohort, IRLA leads on earnings valuation at N/A trailing P/E, while IRLA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. SCTX currently holds the highest overall quantitative score in the immediate peer group at 50/100 (D) compared with IRLA at 32/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
IRLA ACTIVE IRulya Therapeutics Inc.	E	32/100	—	—	-35.0%	-4.05%	$342.8M	Benchmark Subject
XFOR X4 Pharmaceuticals Inc.	D-	35/100	—	83.6%	-35.0%	+0.30%	$333.1M	/xfor-vs-irla →
ALEC Alector Inc.	E	32/100	—	—	-35.0%	-0.44%	$332.1M	/alec-vs-irla →
SCTX Scribe Therapeutics Inc.	D	50/100	—	—	—	-0.57%	$330.2M	/sctx-vs-irla →
KYTX Kyverna Therapeutics Inc.	D-	42/100	—	—	-35.0%	-0.68%	$361.8M	/kytx-vs-irla →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001662774

In its most recent audited fiscal period (FY2025, filed 2025-12-31), IRulya Therapeutics Inc. (IRLA) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$84.0M, operating cash flow of -$41.4M, and free cash flow of -$41.8M (-29.9% YoY). On the balance sheet, IRLA closed FY2025 with $93.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$84.0M	-$41.4M	-$41.8M	$93.5M	—
FY2024 (FY)	2024-12-31	$0	-$56.8M	-$31.9M	-$32.2M	$114.5M	—
FY2023 (FY)	2023-12-31	$0	-$31.4M	-$18.3M	-$18.3M	—	—

3. IRLA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is IRLA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, IRulya Therapeutics Inc. (NASDAQ: IRLA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $31.62 (-4.05% 1D, market cap $342.8M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, IRLA ranks #889 in composite RQD confidence.

How does IRLA compare to XFOR and ALEC in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), IRLA carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, XFOR (X4 Pharmaceuticals Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $333.1M) and ALEC (Alector Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $332.1M). Among the 5-stock peer group, IRLA leads on earnings multiple (N/A) while IRLA leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for IRLA?

Per IRLA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001662774), IRulya Therapeutics Inc. generated $0 in revenue, -$84.0M in net income, and -$41.8M in free cash flow against $93.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is IRLA trading relative to its 50-day, 200-day, and 52-week technical levels?

IRLA last traded at $31.62 (-4.05% on volume of 64,273 shares), positioning the stock +1.77% above its 50-day simple moving average ($31.07) and -41.94% below its 200-day simple moving average ($54.46). Across its 52-week range of $15.10 to $910.00, IRLA sits at the 1.8% percentile with a 14-day RSI of 52.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($27.67 to $35.57).

IRLA Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does IRLA pay a dividend and is it safe?

IRulya Therapeutics Inc. (IRLA) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: IRLA RQD Cockpit IRLA 12M Forecast IRLA Earnings & Move IRLA Dividends & DRIP IRLA Insiders & 13F IRLA Whale Options IRLA Profit Sankey IRLA News & Why